After Hours
$
92.00
Change
+0.21 +0.23%
Volume
Volume 27,964
Sep 26, 2023, 7:59 p.m.
Quotes are delayed by 20 min
Previous close
$ 91.13
$ 91.79
Change
+0.66 +0.72%
Day low
Day high
$91.54
$92.97

52 week low
52 week high
$48.59
$100.88

Market cap
$356.26B
Average volume
3.91M
P/E ratio
21.80
Rev. per Employee
$521,882
EPS
4.21
Dividend
0.88
Div yield
0.80%
Ex dividend date
8/18/23
MarketWatch News on NVO
-
Snack Stock Utz May Be a Buy, Says Analyst
- Angela Palumbo
-
Novo Nordisk partners with Valo Health on AI drug discovery
- Eleanor Laise
-
Medtech Makers Are Real Losers From Obesity Drugs
- Bill Alpert
-
Will Obesity Drugs Break the Healthcare System?
- Josh Nathan-Kazis
-
DoorDash Warns About Grocery Delivery: It’s Hard
- Eric J. Savitz
-
Food Stocks Have Gotten Hit Hard. 6 to Buy Now.
- Andrew Bary
-
ResMed shares can overcome obesity-drug craze, analysts say
- Eleanor Laise
-
Stocks and bonds are out of balance. Here’s what could come next.
- Steve Goldstein
-
Novo Nordisk Is Europe’s Biggest Company. Wegovy Helps.
- Brian Swint
-
First 10 Drugs Picked for Medicare Price Negotiations
- Bill Alpert
-
Amazon Pharmacy launches automatic coupons for $35 insulin
- Eleanor Laise
- Loading more headlines...
Analyst Ratings
-
Analysts See a 9.5% Upside for SNY Stock over the Next Year
- MarketRealist.com
-
Analysts’ Updates after Sanofi’s Bioverativ Announcement
- MarketRealist.com
Other News on NVO
-
The Big Pharma Trade: Ozempic Is In, Covid-19 Is Out
- Charley Grant
-
A New Way to Protect Against Heart Attacks
- Ron Winslow
-
Contamination Found at Novo Nordisk Plant in U.S.
- Peter Loftus
-
Asian Markets Rise on China’s Property Stimulus Measures
- Will Horner
-
Drug Price Controls Mean Slower Cures
- The Editorial Board
-
Expensive Drugs Targeted for First U.S. Price Negotiations
- Jared S. Hopkins
-
Weight-Loss Drug Wegovy Also Works Against Heart Failure
- Peter Loftus
-
The Ozempic Craze Could Put These Companies on a Crash Diet
- David Wainer
-
The Score: Eli Lilly, WeWork, Walt Disney and More Stocks That Defined the Week
- Francesca Fontana
-
Weight-Loss Drug Wegovy Cuts Heart Risk in New Study
- Peter Loftus
-
The Obesity Drug Revolution Just Got Real
- David Wainer
-
Drug Shortages Are a Boon to One Industry: Compounding Pharmacies
- Jared S. Hopkins
-
U.K. Reviews Safety of Ozempic, Other Weight-Loss Drugs
- Peter Loftus
-
Drugs Like Ozempic Created a Gold Rush. These Drugmakers Want In.
- Jared S. Hopkins
- Loading more headlines...
Press Releases on NVO
-
JV Partner Liatam Mining Outlines Lithium Exploration Program
- GlobeNewswire
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com